{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:33:05Z","timestamp":1792989185935,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100023174","name":"Kementerian Pendidikan, Kebudayaan, Riset, dan Teknologi","doi-asserted-by":"publisher","award":["3954\/UN6.3.1\/PT.00\/2024"],"award-info":[{"award-number":["3954\/UN6.3.1\/PT.00\/2024"]}],"id":[{"id":"10.13039\/501100023174","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015690","name":"Universitas Padjadjaran","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015690","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.critrevonc.2025.104895","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T06:43:52Z","timestamp":1755153832000},"page":"104895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Role of Bcl-2 family anti-apoptosis inhibition in overcoming therapeutic resistance in prostate cancer: A systematic review"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-067X","authenticated-orcid":false,"given":"Indra","family":"Jaya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry","family":"Safriadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indra","family":"Wijaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritha","family":"Pitaloka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ervi","family":"Afifah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza Shifa","family":"Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hasan","family":"Bashari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104895_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13050937","article-title":"Signaling pathways that control apoptosis in prostate cancer","volume":"13","author":"Ali","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104895_bib2","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-18-0549","article-title":"Tyrosine kinase inhibitors increase MCL1 degradation and in combination with BCLXL\/BCL2 inhibitors drive prostate cancer apoptosis","volume":"24","author":"Arai","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104895_bib3","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nature08822","article-title":"The landscape of somatic copy-number alteration across human cancers","volume":"463","author":"Beroukhim","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104895_bib4","first-page":"905","article-title":"Cellular senescence: when growth stimulation meets cell cycle arrest","volume":"15","author":"Blagosklonny","year":"2023","journal-title":"Aging"},{"key":"10.1016\/j.critrevonc.2025.104895_bib5","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.1002\/1878-0261.13312","article-title":"Targeting senescence as an anticancer therapy","volume":"16","author":"Bousset","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104895_bib6","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1158\/1541-7786.MCR-09-0166","article-title":"Bcl-2 modulation to activate apoptosis in prostate cancer","volume":"7","author":"Bray","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104895_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116385","article-title":"Androgen deprivation-induced senescence confers sensitivity to a senolytic strategy in prostate cancer","volume":"226","author":"Carpenter","year":"2024","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.critrevonc.2025.104895_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114765","article-title":"Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy","volume":"193","author":"Carpenter","year":"2021","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.critrevonc.2025.104895_bib9","article-title":"Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics","volume":"13","author":"Carter","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2025.104895_bib10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104895_bib11","article-title":"Potassium channels in intestinal epithelial cells and their pharmacological modulation: a systematic review","author":"Cosme","year":"2020","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.critrevonc.2025.104895_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104895_bib13","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1042\/BST20210750","article-title":"Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers","volume":"49","author":"Fairlie","year":"2021","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.critrevonc.2025.104895_bib14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/hematology.2020000120","article-title":"Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia","volume":"2020","author":"Fischer","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.critrevonc.2025.104895_bib15","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200195","article-title":"Meta-analysis of candidate surrogate end points in advanced prostate cancer","volume":"2","author":"Gharzai","year":"2023","journal-title":"NEJM Evid."},{"key":"10.1016\/j.critrevonc.2025.104895_bib16","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ccell.2020.10.012","article-title":"Senescence reprogramming by TIMP1 deficiency promotes prostate cancer metastasis","volume":"39","author":"Guccini","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2025.104895_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms26020802","article-title":"Exosomal liquid biopsy in prostate cancer: a systematic review of biomarkers for diagnosis, prognosis, and treatment response","volume":"26","author":"Hamid","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104895_bib18","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/2159-8290.CD-15-0011","article-title":"The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics","volume":"5","author":"Hata","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104895_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","author":"He","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2025.104895_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","author":"Heitzer","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.critrevonc.2025.104895_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115779","article-title":"BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways","volume":"44","author":"Hirani","year":"2025","journal-title":"Cell Rep"},{"key":"10.1016\/j.critrevonc.2025.104895_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2019.02.007","article-title":"Recent advances in the development of Mcl-1 inhibitors for cancer therapy","volume":"198","author":"Hird","year":"2019","journal-title":"Pharm. Ther."},{"key":"10.1016\/j.critrevonc.2025.104895_bib23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1593\/neo.12640","article-title":"Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer","volume":"14","author":"Jackson","year":"2012","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2025.104895_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10495-022-01780-7","article-title":"BCL-2 protein family: attractive targets for cancer therapy","volume":"28","author":"Kaloni","year":"2023","journal-title":"Apoptosis"},{"key":"10.1016\/j.critrevonc.2025.104895_bib25","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/bs.apcsb.2021.01.003","article-title":"Intrinsic and extrinsic pathways of apoptosis: role in cancer development and prognosis","volume":"125","author":"Kashyap","year":"2021","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"10.1016\/j.critrevonc.2025.104895_bib26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2015.06.021","article-title":"Androgen deprivation of prostate cancer: leading to a therapeutic dead end","volume":"367","author":"Katzenwadel","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2025.104895_bib27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104895_bib28","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1158\/1078-0432.CCR-20-3260","article-title":"Emergence of enzalutamide resistance in prostate cancer is associated with BCL-2 and IKKB dependencies","volume":"27","author":"Liang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104895_bib29","first-page":"139","article-title":"Direct activation of bax protein for cancer therapy","volume":"176","author":"Liu","year":"2017","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.critrevonc.2025.104895_bib30","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.104895_bib31","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.144","article-title":"ABT-737, a small molecule Bcl-2\/Bcl-xL antagonist, increases antimitoticmediated apoptosis in human prostate cancer cells","author":"Parrondo","year":"2013","journal-title":"PeerJ"},{"key":"10.1016\/j.critrevonc.2025.104895_bib32","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/pros.23843","article-title":"Targeting prosurvival BCL2 signaling through akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide","volume":"79","author":"Pilling","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.critrevonc.2025.104895_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-020-00422-2","article-title":"Senolytic compounds control a distinct fate of androgen receptor agonist- and antagonist-induced cellular senescent LNCaP prostate cancer cells","volume":"10","author":"Pungsrinont","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.critrevonc.2025.104895_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2022.985363","article-title":"The role of BCL-2 family proteins in regulating apoptosis and cancer therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104895_bib35","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/0008-5472.CAN-12-1365","article-title":"Dual inhibition of Bcl-2 and Bcl-xL Strikingly Enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and bim-dependent mechanism","volume":"73","author":"Rahmani","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104895_bib36","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104895_bib37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104895_bib38","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.eururo.2020.10.001","article-title":"Taxane-induced attenuation of the CXCR2\/BCL-2 axis sensitizes prostate cancer to Platinum-based treatment","volume":"79","author":"Ruiz de Porras","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104895_bib39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.104895_bib40","doi-asserted-by":"crossref","first-page":"13762","DOI":"10.1021\/acs.jmedchem.0c01234","article-title":"Discovery of S64315, a potent and selective Mcl-1 inhibitor","volume":"63","author":"Szlavik","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.critrevonc.2025.104895_bib41","doi-asserted-by":"crossref","first-page":"11399","DOI":"10.18632\/oncotarget.2550","article-title":"Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition","volume":"5","author":"Tamaki","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.104895_bib42","unstructured":"Teo, M.Y., Rathkopf, D.E., Kantoff, P., 2018. Treatment of Advanced Prostate Cancer. doi:10.1146\/annurev-med-051517."},{"key":"10.1016\/j.critrevonc.2025.104895_bib43","article-title":"Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells","volume":"10","author":"Wang","year":"2015","journal-title":"PLOS One"},{"key":"10.1016\/j.critrevonc.2025.104895_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy","author":"Vogler","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"20","key":"10.1016\/j.critrevonc.2025.104895_bib45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/hematology.2020000089","article-title":"Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop","author":"Wang","year":"2020","journal-title":"Hematol."},{"key":"10.1016\/j.critrevonc.2025.104895_bib46","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.2024027117","article-title":"Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104895_bib47","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104895_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040831","article-title":"Preclinical study using ABT263 to increase enzalutamide sensitivity to suppress prostate cancer progression via targeting BCL2\/ROS\/USP26 axis through altering ARv7 protein degradation","volume":"12","author":"Xu","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104895_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers15204957","article-title":"Current advances and future strategies for BCL-2 inhibitors: potent weapons against cancers","volume":"15","author":"Xu","year":"2023","journal-title":"Cancers"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:43:14Z","timestamp":1792986194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":49,"alternative-id":["S1040842825002835"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104895","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Bcl-2 family anti-apoptosis inhibition in overcoming therapeutic resistance in prostate cancer: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104895"}}